View in EDS HTML Full Text PDF Full Text

Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP‐RCC study.

Saved in:
Bibliographic Details
Title: Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP‐RCC study.
Authors: Blas, Leandro1 (AUTHOR), Shiota, Masaki1 (AUTHOR) shiota.masaki.101@m.kyushu-u.ac.jp, Miyake, Hideaki2 (AUTHOR), Takahashi, Masayuki3 (AUTHOR), Oya, Mototsugu4 (AUTHOR), Tsuchiya, Norihiko5 (AUTHOR), Masumori, Naoya6 (AUTHOR), Matsuyama, Hideyasu7 (AUTHOR), Obara, Wataru8 (AUTHOR), Shinohara, Nobuo9 (AUTHOR), Fujimoto, Kiyohide10 (AUTHOR), Nozawa, Masahiro11 (AUTHOR), Ohba, Kojiro12 (AUTHOR), Ohyama, Chikara13 (AUTHOR), Hashine, Katsuyoshi14 (AUTHOR), Akamatsu, Shusuke15 (AUTHOR), Kamba, Tomomi16 (AUTHOR), Mita, Koji17 (AUTHOR), Gotoh, Momokazu18 (AUTHOR), Tatarano, Shuichi19 (AUTHOR)
Source: International Journal of Urology. Sep2023, Vol. 30 Issue 9, p788-796. 9p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:09198172
DOI:10.1111/iju.15265